WO2003104247A3 - Cdg-therapie mit mannose - Google Patents

Cdg-therapie mit mannose Download PDF

Info

Publication number
WO2003104247A3
WO2003104247A3 PCT/EP2003/005986 EP0305986W WO03104247A3 WO 2003104247 A3 WO2003104247 A3 WO 2003104247A3 EP 0305986 W EP0305986 W EP 0305986W WO 03104247 A3 WO03104247 A3 WO 03104247A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosilation
disorders
denote
mannose
congenital
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/005986
Other languages
English (en)
French (fr)
Other versions
WO2003104247A2 (de
Inventor
Thorsten Marquardt
Joachim Thiem
Synke Rutschow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHS GESELLSCHAFT fur KLINISCHE ERNAEHRUNG MBH
SHS GES fur KLINISCHE ERNAEHR
Original Assignee
SHS GESELLSCHAFT fur KLINISCHE ERNAEHRUNG MBH
SHS GES fur KLINISCHE ERNAEHR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHS GESELLSCHAFT fur KLINISCHE ERNAEHRUNG MBH, SHS GES fur KLINISCHE ERNAEHR filed Critical SHS GESELLSCHAFT fur KLINISCHE ERNAEHRUNG MBH
Priority to AU2003246402A priority Critical patent/AU2003246402A1/en
Priority to DE50302198T priority patent/DE50302198D1/de
Priority to EP03757039A priority patent/EP1521761B1/de
Publication of WO2003104247A2 publication Critical patent/WO2003104247A2/de
Publication of WO2003104247A3 publication Critical patent/WO2003104247A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Bereitgestellt werden Mannose 1-Phosphat Derivate und diese enthaltende pharmazeutische oder diätetische Mittel zur Behandlung von Glykosylierungsstörungen und insbesondere zur Behandlung von CDG-la. Diese Derivate besitzen die folgende allgemeine Formel (I), worin R<1> und R<2>, die gleich oder verschieden sein können, für H oder (II) stehen, oder R<1> und R<2> zusammen für Formel (III) stehen, mit der Massgabe, dass nur einer der Reste R<1> und R<2> für H stehen kann, und R<3> und R<4>, die gleich oder verschieden sein können, für (a), (b), (c) und (d) stehen und der Rest R<3> auch für H stehen kann, wobei Aryl einen aromatischen Kohlenwasserstoffrest bedeutet, der durch einen Rest Alkyl substituiert sein, und Alkyl einen linearen oder verzweigten, gesättigen kohlenwasserrstoffrest mit 1 bis 20 Kohlenstoffatomen bedeutet.
PCT/EP2003/005986 2002-06-07 2003-06-06 Cdg-therapie mit mannose Ceased WO2003104247A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003246402A AU2003246402A1 (en) 2002-06-07 2003-06-06 Treatment of congenital disorders of glycosylation (cdg) using mannose
DE50302198T DE50302198D1 (de) 2002-06-07 2003-06-06 Cdg-therapie mit mannose
EP03757039A EP1521761B1 (de) 2002-06-07 2003-06-06 Cdg-therapie mit mannose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225628A DE10225628A1 (de) 2002-06-07 2002-06-07 CDG-Therapie mit Mannose
DE10225628.4 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003104247A2 WO2003104247A2 (de) 2003-12-18
WO2003104247A3 true WO2003104247A3 (de) 2004-02-12

Family

ID=29594345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005986 Ceased WO2003104247A2 (de) 2002-06-07 2003-06-06 Cdg-therapie mit mannose

Country Status (5)

Country Link
EP (1) EP1521761B1 (de)
AT (1) ATE315570T1 (de)
AU (1) AU2003246402A1 (de)
DE (2) DE10225628A1 (de)
WO (1) WO2003104247A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2897779B1 (fr) * 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
EP2972390B1 (de) 2013-03-14 2017-11-08 The United States Of America, As Represented By The Sectretary, Department Of Health And Human Services Hyposialylierungsstörungen
US10493087B2 (en) 2015-02-25 2019-12-03 The United States of America, as represented by National Institute of Health Sialylation-increasing therapies for diseases associated with oxidative stress
CA3110162A1 (en) * 2018-08-20 2020-02-27 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRÜNEWALD, S. ET AL.: "Congenital disorders of glycosylation: a review", PEDIAT.RES., vol. 52, no. 5, 2002, pages 618 - 624, XP009019434 *
KNERR, LAURENT ET AL: "Efficient synthesis of hydrophilic phosphodiester derivatives of lipophilic alcohols via the glycosyl hydrogenphosphonate method", TETRAHEDRON LETTERS (1998), 39(3/4), 273-274, XP004100940 *
MAYATEPEK, E. ET AL.: "Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency", EUR. J. PEDIAT., vol. 157, 1998, pages 605 - 606, XP002259389 *
RUTSCHOW, SYNKE ET AL: "Membrane-Permeant derivatives of mannose-1-phosphate", BIOORGANIC & MEDICINAL CHEMISTRY (2002), 10(12), 4043-4049, XP002259386 *
WARREN, C. D. ET AL.: "Chemical synthesis of dolichyl- alpha-D-mannopyranosyl phosphate and citronellyl-alpha-D-mannopyranosyl phosphate", BIOCHEM., vol. 12, no. 25, 1973, pages 5038 - 5044, XP002259388 *

Also Published As

Publication number Publication date
ATE315570T1 (de) 2006-02-15
DE10225628A1 (de) 2003-12-24
EP1521761A2 (de) 2005-04-13
AU2003246402A1 (en) 2003-12-22
WO2003104247A2 (de) 2003-12-18
DE50302198D1 (de) 2006-04-06
EP1521761B1 (de) 2006-01-11

Similar Documents

Publication Publication Date Title
FR2714378B1 (fr) Dérivés de l&#39;indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
ATE196140T1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN99147A1 (fr) Procede d&#39;emulsification
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
TNSN99053A1 (fr) Hydroxamides d&#39;acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9210400D0 (en) Therapeutic agents
BR9508295A (pt) Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
ES2105286T3 (es) Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria.
KR960006915A (ko) 췌장염의 치료 조성물
TNSN97204A1 (fr) Derives de pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
AUPO111096A0 (en) New compound
TNSN99080A1 (fr) Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
WO2003104247A3 (de) Cdg-therapie mit mannose
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1&#39;- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
PL330284A1 (en) Chemical compounds having a colchicine skeleton, their application as drugs and compositions containing such compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BR BY CA CN HR ID IL IN JP LT LV MK NO NZ PL RU SG UA US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003757039

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003757039

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003757039

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP